“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A study looking at irosustat for early breast cancer (IPET)
This study looked at irosustat for women who had been through the menopause and had early stage, oestrogen receptor positive (ER positive) breast cancer.
More about this trial
Most breast cancers in post menopausal women need a
Women in this study had irosustat for 2 weeks while they were waiting to have their planned treatment. During this time they had 2 scans called FLT PET scans. The researchers used these scans to see if irosustat can slow or stop the growth of the cancer.
The aim of this study was to use FLT PET scans to find out if irosustat can stop or slow the growth of early stage, ER positive breast cancer.
Summary of results
This study recruited 13 women with early stage breast cancer, and the research team were able to analyse the results of 8 of them.
The team had hoped to recruit more women. But they found it quite difficult to find people who were able to, and wanted to, join the trial.
All the women taking part had been through the menopause and had oestrogen receptor positive breast cancer. They were all due to either have surgery to remove their cancer, or have treatment to shrink it before surgery. They all:
- had already had a biopsy to diagnose their cancer
- had an FLT PET scan before they started treatment
- took irosustat tablets once a day, for at least 2 weeks
- had another FLT PET scan
7 of the women taking part also had another biopsy taken during their operation, after taking irosustat.
The research team measured how well the irosustat worked in several ways. One was using the results of the FLT PET scans.
When you have a FLT PET scan, you have an injection of a small amount of radioactive drug (a tracer) into a vein. This is absorbed by cancer cells, and these cells show up on the scan. Doctors compare how much of the tracer is absorbed before and after treatment. If less of the tracer is absorbed, this can mean the cancer cells are growing more slowly.
The results showed that the average amount of tracer absorbed was lower in 4 out of the 8 women (50%). It was a bit lower in 3 of these women, and was significantly lower in 1 woman.
They also looked at the level of a specific protein in the biopsy samples which is involved with cell growth. They found that after irosustat there was less of this protein in 6 out of 7 biopsy samples (85%).
The women taking part did not have any serious side effects. Some women had mild side effects that didn’t last long. The most common side effect was dry skin.
The study team concluded that irosustat was safe to use and could be a useful treatment for early stage breast cancer. They suggest more research with larger trials to find out more about how well it works.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Biomedical Research Centre
Imperial Clinical Trials Unit – Cancer (ICTU-Ca)
Imperial College Healthcare NHS Trust